EGFR and lung carcinoma: Although this study still requires validation with larger sample sizes and longer follow-up data, it provides the first evidence of “clinical cure by immunotherapy monotherapy” for advanced lung cancer with EGFR-TKI acquired resistance, offering a new paradigm for overcoming the clinical challenge of targeted therapy resistance.